Your browser doesn't support javascript.
loading
Prospective External Validation of the Esbenshade Vanderbilt Models Accurately Predicts Bloodstream Infection Risk in Febrile Non-Neutropenic Children With Cancer.
Zhao, Zhiguo; Patel, Pratik A; Slatnick, Leonora; Sitthi-Amorn, Anna; Bielamowicz, Kevin J; Nunez, Farranaz A; Walsh, Alexandria M; Hess, Jennifer; Rossoff, Jenna; Elgarten, Caitlin; Myers, Regina; Saab, Raya; Basbous, Maya; Mccormick, Meghan; Aftandilian, Catherine; Richards, Rebecca; Nessle, C Nathan; Tribble, Alison C; Sheth Bhutada, Jessica K; Coven, Scott L; Runco, Daniel; Wilkes, Jennifer; Gurunathan, Arun; Guinipero, Terri; Belsky, Jennifer A; Lee, Karen; Wong, Victor; Malhotra, Megha; Armstrong, Amy; Jerkins, Lauren P; Cross, Shane J; Fisher, Lyndsay; Stein, Madison T; Wu, Natalie L; Yi, Troy; Orgel, Etan; Haeusler, Gabrielle M; Wolf, Joshua; Demedis, Jenna M; Miller, Tamara P; Esbenshade, Adam J.
Afiliación
  • Zhao Z; Department of Biostatistics, Vanderbilt University Medical Center and the Vanderbilt-Ingram Cancer Center, Nashville, TN.
  • Patel PA; Pediatric Hematology/Oncology, Emory University School of Medicine and Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA.
  • Slatnick L; Department of Pediatrics, Section of Pediatric Hematology/Oncology, University of Colorado Anschutz Medical Center, Children's Hospital Colorado, Aurora, CO.
  • Sitthi-Amorn A; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN.
  • Bielamowicz KJ; University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, AR.
  • Nunez FA; University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, AR.
  • Walsh AM; Phoenix Children's Hospital, Phoenix, AZ.
  • Hess J; Phoenix Children's Hospital, Phoenix, AZ.
  • Rossoff J; Department of Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL.
  • Elgarten C; Children's Hospital of Philadelphia, Division of Oncology, Philadelphia, PA.
  • Myers R; Children's Hospital of Philadelphia, Division of Oncology, Philadelphia, PA.
  • Saab R; Children's Cancer Institute, Department of Pediatrics, American University of Beirut Medical Center, Beirut, Lebanon.
  • Basbous M; Children's Cancer Institute, Department of Pediatrics, American University of Beirut Medical Center, Beirut, Lebanon.
  • Mccormick M; University of Pittsburgh Medical Center, Pittsburgh, PA.
  • Aftandilian C; Department of Pediatric Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine Stanford University, Palo Alto, CA.
  • Richards R; Department of Pediatric Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine Stanford University, Palo Alto, CA.
  • Nessle CN; Department of Pediatrics, Division of Pediatric Hematology Oncology, University of Michigan, Ann Arbor, MI.
  • Tribble AC; Department of Pediatrics, Division of Pediatric Infectious Diseases, University of Michigan, Ann Arbor, MI.
  • Sheth Bhutada JK; Cancer and Blood Disease Institute, Children's Hospital of Los Angeles, Los Angeles, CA.
  • Coven SL; Keck School of Medicine, University of Southern California, Los Angeles, CA.
  • Runco D; Department of Pediatrics, Division of Pediatric Hematology/Oncology, Department of Pediatrics, Division of Pediatric Hematology/Oncology, Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, IN.
  • Wilkes J; Department of Pediatrics, Division of Pediatric Hematology/Oncology, Department of Pediatrics, Division of Pediatric Hematology/Oncology, Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, IN.
  • Gurunathan A; Division of Pediatric Hematology and Oncology and Bone Marrow Transplant, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA.
  • Guinipero T; Division of Pediatric Hematology and Oncology and Bone Marrow Transplant, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA.
  • Belsky JA; Department of Pediatrics, Division of Pediatric Hematology and Oncology, Nationwide Children's Hospital, Columbus, OH.
  • Lee K; Department of Pediatrics, Division of Pediatric Hematology/Oncology, Department of Pediatrics, Division of Pediatric Hematology/Oncology, Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, IN.
  • Wong V; Department of Pediatrics, Division of Pediatric Hematology and Oncology, Rady Children's Hospital San Diego, University of California San Diego, San Diego, CA.
  • Malhotra M; Department of Pediatrics, Division of Pediatric Hematology and Oncology, Rady Children's Hospital San Diego, University of California San Diego, San Diego, CA.
  • Armstrong A; Department of Pediatrics, Division of Pediatric Hematology and Oncology, Washington University in St Louis School of Medicine, St Louis, MO.
  • Jerkins LP; Department of Pediatrics, Division of Pediatric Hematology and Oncology, Washington University in St Louis School of Medicine, St Louis, MO.
  • Cross SJ; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN.
  • Fisher L; Department of Pharmacy and Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN.
  • Stein MT; University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, AR.
  • Wu NL; Children's Hospital of Philadelphia, Division of Oncology, Philadelphia, PA.
  • Yi T; Division of Pediatric Hematology and Oncology and Bone Marrow Transplant, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA.
  • Orgel E; Division of Pediatric Hematology and Oncology and Bone Marrow Transplant, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA.
  • Haeusler GM; Cancer and Blood Disease Institute, Children's Hospital of Los Angeles, Los Angeles, CA.
  • Wolf J; Keck School of Medicine, University of Southern California, Los Angeles, CA.
  • Demedis JM; Department of Infectious Diseases, Royal Children's Hospital, Melbourne, Australia.
  • Miller TP; Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN.
  • Esbenshade AJ; Department of Pediatrics, Section of Pediatric Hematology/Oncology, University of Colorado Anschutz Medical Center, Children's Hospital Colorado, Aurora, CO.
J Clin Oncol ; 42(7): 832-841, 2024 Mar 01.
Article en En | MEDLINE | ID: mdl-38060973
PURPOSE: The optimal management of fever without severe neutropenia (absolute neutrophil count [ANC] ≥500/µL) in pediatric patients with cancer is undefined. The previously proposed Esbenshade Vanderbilt (EsVan) models accurately predict bacterial bloodstream infections (BSIs) in this population and provide risk stratification to aid management, but have lacked prospective external validation. MATERIALS AND METHODS: Episodes of fever with a central venous catheter and ANC ≥500/µL occurring in pediatric patients with cancer were prospectively collected from 18 academic medical centers. Variables included in the EsVan models and 7-day clinical outcomes were collected. Five versions of the EsVan models were applied to the data with calculation of C-statistics for both overall BSI rate and high-risk organism BSI (gram-negative and Staphylococcus aureus BSI), as well as model calibration. RESULTS: In 2,565 evaluable episodes, the BSI rate was 4.7% (N = 120). Complications for the whole cohort were rare, with 1.1% (N = 27) needing intensive care unit (ICU) care by 7 days, and the all-cause mortality rate was 0.2% (N = 5), with only one potential infection-related death. C-statistics ranged from 0.775 to 0.789 for predicting overall BSI, with improved accuracy in predicting high-risk organism BSI (C-statistic 0.800-0.819). Initial empiric antibiotics were withheld in 14.9% of episodes, with no deaths or ICU admissions attributable to not receiving empiric antibiotics. CONCLUSION: The EsVan models, especially EsVan2b, perform very well prospectively across multiple academic medical centers and accurately stratify risk of BSI in episodes of non-neutropenic fever in pediatric patients with cancer. Implementation of routine screening with risk-stratified management for non-neutropenic fever in pediatric patients with cancer could safely reduce unnecessary antibiotic use.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Infecciones Bacterianas / Bacteriemia / Sepsis / Infecciones / Neoplasias Límite: Child / Humans Idioma: En Revista: J Clin Oncol Año: 2024 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Infecciones Bacterianas / Bacteriemia / Sepsis / Infecciones / Neoplasias Límite: Child / Humans Idioma: En Revista: J Clin Oncol Año: 2024 Tipo del documento: Article